Tailoring stepwise treatment for Budd-Chiari syndrome: insights from the Asian Pacific Association for the Study of the Liver (APASL) consensus guidance
- PMID: 36860254
- PMCID: PMC9944543
- DOI: 10.21037/hbsn-22-584
Tailoring stepwise treatment for Budd-Chiari syndrome: insights from the Asian Pacific Association for the Study of the Liver (APASL) consensus guidance
Keywords: Budd-Chiari syndrome (BCS); anticoagulation; guidelines; hepatic venous outflow obstruction; liver transplantation; surgery; transjugular intrahepatic portosystemic shunts (TIPS).
Conflict of interest statement
Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-22-584/coif). JKL reports research contracts to Yale University from Celgene, Eiger, Genfit, Gilead, Intercept, Inventiva, Pfizer, Viking. The other author has no conflicts of interest to declare.
Comment on
-
Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).Hepatol Int. 2021 Jun;15(3):531-567. doi: 10.1007/s12072-021-10189-4. Epub 2021 Jul 8. Hepatol Int. 2021. PMID: 34240318
References
-
- Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021;73:366-413. 10.1002/hep.31646 - DOI - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources